Literature DB >> 20160209

Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy.

Torricia H Yamada1, Natalie L Denburg, Leigh J Beglinger, Susan K Schultz.   

Abstract

The authors examined the long-term cognitive implications of cancer treatment among breast cancer survivors over 65 years old who received treatment during midlife. Thirty women survivors were matched with 30 noncancer, healthy older adults in terms of age, education, and IQ. The cancer survivors scored significantly lower in the cognitive domains of executive functioning, working memory, and divided attention, reflecting potential dysfunction in frontal-subcortical brain regions. Our findings suggest that among breast cancer survivors who remain disease-free for more than a decade, the previous cancer treatment may further augment cognitive dysfunction associated with age-related brain changes.

Entities:  

Mesh:

Year:  2010        PMID: 20160209      PMCID: PMC3641161          DOI: 10.1176/jnp.2010.22.1.48

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  9 in total

1.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Authors:  Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Computerized assessment in neuropsychiatry using CANTAB: discussion paper.

Authors:  B J Sahakian; A M Owen
Journal:  J R Soc Med       Date:  1992-07       Impact factor: 5.344

4.  Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.

Authors:  S B Schagen; F S van Dam; M J Muller; W Boogerd; J Lindeboom; P F Bruning
Journal:  Cancer       Date:  1999-02-01       Impact factor: 6.860

Review 5.  Attention and executive deficits in Alzheimer's disease. A critical review.

Authors:  R J Perry; J R Hodges
Journal:  Brain       Date:  1999-03       Impact factor: 13.501

Review 6.  Cognitive function after systemic therapy for breast cancer.

Authors:  J J Olin
Journal:  Oncology (Williston Park)       Date:  2001-05       Impact factor: 2.990

7.  Cognitive function in breast cancer patients receiving adjuvant chemotherapy.

Authors:  C B Brezden; K A Phillips; M Abdolell; T Bunston; I F Tannock
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

Review 8.  Cognitive effects of standard-dose chemotherapy in patients with cancer.

Authors:  T A Ahles; A Saykin
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

9.  Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature.

Authors:  Cay Anderson-Hanley; Marne L Sherman; Raine Riggs; V Bede Agocha; Bruce E Compas
Journal:  J Int Neuropsychol Soc       Date:  2003-11       Impact factor: 2.892

  9 in total
  45 in total

Review 1.  An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors.

Authors:  Yin Ting Cheung; Earl Hsien-Jie Tan; Alexandre Chan
Journal:  Support Care Cancer       Date:  2012-04-05       Impact factor: 3.603

Review 2.  Chemotherapy-related cognitive dysfunction.

Authors:  Jeffrey S Wefel; Sanne B Schagen
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

3.  Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial.

Authors:  K Milbury; A Chaoul; K Biegler; T Wangyal; A Spelman; C A Meyers; B Arun; J L Palmer; J Taylor; L Cohen
Journal:  Psychooncology       Date:  2013-05-09       Impact factor: 3.894

Review 4.  An update on cancer- and chemotherapy-related cognitive dysfunction: current status.

Authors:  Michelle C Janelsins; Sadhna Kohli; Supriya G Mohile; Kenneth Usuki; Tim A Ahles; Gary R Morrow
Journal:  Semin Oncol       Date:  2011-06       Impact factor: 4.929

5.  Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy.

Authors:  Vincent Koppelmans; Marius de Groot; Michiel B de Ruiter; Willem Boogerd; Caroline Seynaeve; Meike W Vernooij; Wiro J Niessen; Sanne B Schagen; Monique M B Breteler
Journal:  Hum Brain Mapp       Date:  2012-12-20       Impact factor: 5.038

Review 6.  Cancer 'survivor-care': II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment).

Authors:  R B Raffa
Journal:  J Clin Pharm Ther       Date:  2013-05-08       Impact factor: 2.512

Review 7.  Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors.

Authors:  Jeanne S Mandelblatt; Paul B Jacobsen; Tim Ahles
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

Review 8.  Brain vulnerability to chemotherapy toxicities.

Authors:  Tim A Ahles
Journal:  Psychooncology       Date:  2012-10-01       Impact factor: 3.894

Review 9.  Systemic therapies and cognitive impairment for breast cancer: an overview of the current literature.

Authors:  Icro Meattini; Isacco Desideri; Giulio Francolini; Agnese Vannini; Marco Perna; Pietro Garlatti; Roberta Grassi; Lorenzo Livi
Journal:  Med Oncol       Date:  2017-03-31       Impact factor: 3.064

10.  Frontal hypometabolism in elderly breast cancer survivors determined by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study.

Authors:  Laura L Boles Ponto; Yusuf Menda; Vincent A Magnotta; Torricia H Yamada; Natalie L Denburg; Susan K Schultz
Journal:  Int J Geriatr Psychiatry       Date:  2014-09-01       Impact factor: 3.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.